HealthLynked signs Definitive Agreement to Acquire HCFM,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
16
HealthLynked signs Definitive Agreement to Acquire HCFM, Adding Significant Revenue to its Health Services Division

NAPLES, Fla., Jan. 22, 2019 (GLOBE NEWSWIRE) -- HealthLynked Corp (OTCQB: HLYK),  a leading digital healthcare business, announced today that it has entered into a definitive agreement to acquire Hughes Center for Functional Medicine, P.A. ( HCFM) for $750,000 in cash, $750,000 in shares of HealthLynked common stock and $500,000 in a three-year performance-based payout.

HCFM is a leader in functional medicine, focusing on Neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Multiple Sclerosis along with other cutting-edge treatments to improve health and slow aging, including hormones, thyroid, weight loss, wellness and prevention. Income sources include seeing patients, an IV room, Hyperbaric Oxygen Chambers, Ozone, UVlrx and Supplements.

“The acquisition of HCFM expands our health services division and significantly adds to our profitability.  HCFM provides expertise in Neurodegenerative conditions and functional medicine with cutting edge therapies.” said Michael Dent, M.D., HealthLynked’s Chairman and CEO.  “As we continue to expand our network and provide algorithms around new and innovative treatments, we are confident that this will bring significant value to our patient members. ” Benefits of the Transaction

  • Revenue and Profit Increase.  HealthLynked expects the acquisition to contribute $3.0 million of revenue and $500 thousand in EBITDA in year one, more than doubling the Company’s revenues and reducing cash burn by over 50%.                                                                                                        
  • Expansion of Healthcare Services.  HCFM has well-established relationships and cutting-edge protocols for treating neurogenerative disorders and optimizing the health of older patients. These customized therapies have been shown to improve patient outcomes for a wide range of disorders. Functional Medicine is one of the fastest growing and most highly profitable areas of healthcare making it an ideal acquisition for HealthLynked.                                                                                                                             
  • Expansion of Healthcare Data Specific to Functional Medicine and Antiaging.  HealthLynked will draw on the best attributes from each company to improve the quality of service for all of our patient members. HCFM patients will benefit from HealthLynked’s digital technology to connect and analyze patient members healthcare data to monitor treatments and improve outcomes.  HealthLynked members will benefit from HCFM health services and extensive experience in functional medicine.                                                                                                                            
  • Four-year Consultancy Agreement with Dr. Pamela Hughes on the HLYK Advisory Board. The acquisition also includes a four-year consultancy agreement with Dr. Pamela Hughes on the HealthLynked Advisory Board where she will provide her expertise in functional medicine to help the Company’s development team to write algorithms utilizing the HealthLynked software to make recommendations to patient members on a wide range of medical conditions.                                                                                                                              
  • Advisors K&L Gates LLP is serving as legal counsel for the acquisition. George O’Leary, Chief Financial Officer of HealthLynked, stated, “We expect that this will be the first of many acquisitions for HealthLynked focused on:
    • Profitable health service businesses;
    • Digital healthcare including online marketing and telemedicine companies; and
    • Data driven healthcare businesses, such as Accountable Care Organizations (ACOs)

Our acquisition model of purchasing high growth, profitable health service businesses paying 4 times adjusted EBITDA, with 35% in cash, 35% in HLYK stock, and 30% in three year performance based payouts will complement our digital healthcare and ACO acquisition strategies.”                        

About HealthLynked Corp.

HealthLynked Corp. provides a solution for both patient members and providers to improve healthcare through the efficient exchange of medical information. The HealthLynked Network is a cloud-based platform that allows members to connect with their healthcare providers and take more control of their healthcare. Members enter their medical information, including medications, allergies, past surgeries and personal health records, in one convenient online and secure location, free of charge.

Participating healthcare providers can connect with their current and future patients through the system. Other benefits to providers include the ability to utilize the HealthLynked marketing tools to connect with their active and inactive patients to improve patient retention, access more accurate and current patient information, provide more efficient online scheduling and to fill last minute cancellations using our “real time appointment scheduling” all within our mobile application. Healthcare providers pay a monthly fee to access these HealthLynked services.

For additional information about HealthLynked Corp. visit www.healthlynked.com and connect with HealthLynked on Twitter , Facebook , and LinkedIn .

Forward Looking Statements

Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Our actual results, including as a result of any acquisitions, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by our management, and us are inherently uncertain. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Certain risks and uncertainties applicable to our operations and us are described in the “ Risk Factors ” section of our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q and in other reports we have filed with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov .                                        

Company Contact: George O’Leary Chief Financial Officer goleary@healthlynked.com

Investor Relations contact: Jim Hock Hanover International Inc. Investor Relations jh@hanoverintlinc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

STMicroelectronics Share Buyback Program: Key Details Uncovered

Updated Category News Views 167

Overview of STMicroelectronics’ Share Repurchase Program STMicroelectronics N.V., the renowned semiconductor giant, has recently provided a comprehensive update regarding its common share repurchase program. This strategic initiative, designed to enhance shareholder value, was initially disclosed in a previous announcement made in June 2024. With a shareholder...

Continue Reading
Penn Mutual Receives Recognition as a Top Employer in Finance

Updated Category News Views 52

Penn Mutual Recognized as One of the Best Workplaces Penn Mutual Life Insurance Company is thrilled to announce that it has been included in the coveted 2024 Fortune Best Workplaces in Financial Services & Insurance List. This honor marks the second time the company has earned a spot, showcasing its commitment to employee well-being and a strong workplace culture. How the...

Continue Reading
Innovative Hairstyling Clippers Revolutionizing Precision Cuts

Updated Category News Views 302

Revolutionizing Hair Cutting with the TRUE EDGE In a world where hairstyling requires both precision and efficiency, a new invention is set to change the way haircuts are delivered. An inventive mind from Texas has recognized that there could be a more effective method for achieving straight lines while cutting or edging hair. This insight led to the development of the...

Continue Reading
Tyler Technologies to Host Earnings Call: Key Details Inside

Updated Category News Views 96

Tyler Technologies Earnings Conference Call Scheduled Tyler Technologies, Inc. (NYSE: TYL) is making strides as it prepares for its third-quarter earnings results conference call. Scheduled for an upcoming Thursday, the call is set to take place at 10:00 a.m. ET and promises to be an informative session for stakeholders, investors, and industry enthusiasts alike....

Continue Reading
Auction Process for Government Bonds by Riksbank Explained

Updated Category News Views 232

Understanding the Riksbank Auction Process for Government Bonds The way Riksbank conducts auctions for government bonds plays a crucial role in determining monetary policies and financial strategies. These auctions allow investors to bid for bonds, which is essential for both investment opportunities and economic stability. Bid Procedure Details On the designated bid...

Continue Reading